With KN buy, GfK aims for allied-health panel

Share this article:

Research giant GfK said it is acquiring Knowledge Networks, a provider of digital research in the US. The acquisition, terms of which were not disclosed, extends over multiple business units, including healthcare.

The company plans to combine Knowledge Networks' physicians' consulting network panel with its US healthcare panel to improve access to difficult-to-reach specialists. These include allied health professionals, such as dentists, NPs, PAs and surgical groups, a source told MM&M.

Knowledge Networks will also be fully integrated into GfK's custom research and media activities in the US. An email sent to clients said that Simon Kooyman, CEO of Knowledge Networks, will become chief operations officer of GfK Custom Research North America.

GfK Group CEO Matthias Hartmann called Knowledge Networks “an important complement” to his firm's US businesses, adding that the acquisition “presents a unique opportunity for GfK to better help clients meet their business objectives with richer insights.”

“The Knowledge Networks team is simply delighted to join GfK,” said Kooyman in a statement.

Knowledge Networks, which was backed by venture investors Oak Investment Partners, Alloy Ventures and Maveron, is expected to generate 2011 sales of about $58 million. The company has offices in New York, Washington DC, New Jersey, Massachusetts, Ohio, Illinois and California.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?